Davalomilast (Example 100) is an PDE4 inhibitor with anti-inflammatory property. Davalomilast can be studied in research for autoimmune diseases and dermatology research.

SCH-1518291 (Compound 27) is an orally active PDE10A inhibitor. SCH-1518291 exhibits antipsychotic activity in an ADHD rat model. SCH-1518291 can be used in research on neurological disorders such as psychosis.

KW-4490 is a selective phosphodiesterase 4 (PDE4) inhibitor. KW-4490 can be used for the researches of inflammation and immunology, such as asthma.

KRAS IN-44 (Compound S2C2M2) is a PDE6D degrader. KRAS IN-44 inhibits PDE6D-dependent KRAS trafficking and KRAS downstream signaling pathways. KRAS IN-44 down-regulates EGF-induced the phosphorylation of PI3K, AKT, and mTOR. KRAS IN-44 increases Apoptosis. KRAS IN-44 has antitumor activity against hepatoblastoma.

Tilivapram (AVE8112) is an orally active PDE4 inhibitor. Tilivapram can regulate neurophysiological activities and improve cognitive and memory impairments. Tilivapram can be used in the research of various neuropsychiatric disorders such as schizophrenia and Parkinson's disease.

BMS-341400 is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM. BMS-341400 reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 can be used to study erectile dysfunction.

R-836 is a phosphodiesterase inhibitor. R-836 is a bronchodilator. R-836 can alleviate bronchial constriction caused by antigens or platelet activating factors.

Indolidan (LY195115) is an orally active cardiotonic agent and a selective cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a Ki of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure.

(1R,2R)-Elpipodect ((1R,2R)-MK-8189) is the (1R,2R) enantiomer of Elpipodect). Elpipodect (MK-8189) is an orally active and selective PDE10A inhibitor with a Ki of 29 pM. Elpipodect can be used in research of schizophrenia.

WIN-63291 is a selective and orally active phosphodiesterase (PDE) III inhibitor. WIN-63291 can be used for the research of cardiovascular disease.

Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC50 of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction.

Pyrazole N-Desmethyl sildenafil (Compound 10) is an analog of Sildenafil.

PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (KD=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC50=2.21 nM). PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD+), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer.

P7-2302 inhibits PDE7 and PDE4B with IC50 of 0.18 nM and 77.3 nM. P7-2302 inhibits the efflux of P-gp and BCRP (breast cancer resistance protein), exhibits low uptake in rats brain. P7-2302 can be used as a PET tracer when labeled with 18F.

MP 518 is a PDE inhibitor with antihypertensive properties. MP 518 can inhibit cAMP degradation, causing an increase in ICa, and can also antagonize β-adrenergic stimulation, exerting vasodilation.

Desmethyl thiosildenafil is a phosphodiesterase type 5 (PDE5) inhibitor[1].

Desethyl Sildenafil (Sildenafil impurity C) is the impurity of Sildenafil (IC50 of 134.29 μM).

Cipamfylline is a PDE4 inhibitor that can cause PDE4A4 to accumulate in specific areas of the cell through interaction with the ubiquitin scaffolding protein p62. Cipamfylline can be used in the research of atopic dermatitis.

BMS-341400 mesylate (Compound 6) is an orally active and a selective phosphodiesterase 5 (PDE5) inhibitor, with IC50 of 0.3 nM. BMS-341400 mesylate can be used for research of erectile dysfunction.

BC8-15 is a PDE inhibitor with IC50 values of 0.28, 0.22, and 6.46 µM for inhibiting PDE8A, PDE4A, and PDE7A, respectively. BC8-15 can enhance steroidogenesis in mouse Leydig cells.

ASP9831 is an orally active PDE4 inhibitor. ASP9831 inhibits LSP-induced TNF-α production and has anti-inflammatory activity. ASP9831 can be used in fatty liver disease research.

4-Nitrophenyl phenylphosphonate is a substrate for 5'-nucleotide phosphodiesterase.

(±)-BAY-7081 is a racemate of BAY-7081.

(+)-BAY-7081 is an optical isomer of BAY-7081.

Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.

Dovramilast (CC-11050) is a potent and orally active phosphodiesterase 4 (PDE4) inhibitor, CC-11050 is a promising candidate for host directed therapy of patients with pulmonary TB.

Lodenafil (Hydroxyhomosildenafil) is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).

THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.

MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM.

CRD733 (ASP4901) is a potent, selective cGMP-specific PDE9 (phosphodiesterase 9) inhibitor.